<qa>  What is the peptide vaccine emulsified in Montanide ISA-OUTLINE: Patients receive LMB-2 immunotoxin IV over 30 minutes twice on days 1-3. Patients then receive peptide vaccinations comprising gp100:209-217 210M antigen emulsified in Montanide ISA-51 subcutaneously SC, and MART-1:27-35 vaccine emulsified in Montanide ISA-51 SC on days 4, 5, 6, and 24-27 course 1. After week 8, patients achieving tumor response may receive 1 additional course in the absence of disease progression or unacceptable toxicity. 